Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
Open Access
- 22 October 2015
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 4
Abstract
A number of TP53-MDM2 inhibitors are currently under investigation as therapeutic agents in a variety of clinical trials in patients with TP53 wild type tumors. Not all wild type TP53 tumors are sensitive to such inhibitors. In an attempt to improve selection of patients with TP53 wild type tumors, an mRNA expression signature based on 13 TP53 transcriptional target genes was recently developed (Jeay et al. 2015). Careful reanalysis of TP53 status in the study validation data set of cancer cell lines considered to be TP53 wild type detected TP53 inactivating alterations in 23% of cell lines. The subsequent reanalysis of the remaining TP53 wild type cell lines clearly demonstrated that unfortunately the 13-gene signature cannot predict response to TP53-MDM2 inhibitor in TP53 wild type tumors.Keywords
This publication has 8 references indexed in Scilit:
- A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097eLife, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Profiling Critical Cancer Gene Mutations in Clinical Tumor SamplesPLOS ONE, 2009
- Droplet-Based Microfluidic Systems for High-Throughput Single DNA Molecule Isothermal Amplification and AnalysisAnalytical Chemistry, 2009
- Genome-wide in situ exon capture for selective resequencingNature Genetics, 2007
- Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast OriginCancer Research, 2007
- Robust estimators for expression analysisBioinformatics, 2002